Friday, May 13, 2016

Can other gene therapy developers avoid Glybera's fate?

FiercePharma, by Tracy Staton | May 4, 2016.

Glybera, the treatment for an ultra-rare disease called lipoprotein lipase deficiency approved back in 2012 in Europe, carries a price tag of $1 million.

















GSK has said it won’t price its med anywhere close to $1 million. "We're trying to create a balance between nurturing innovation and creating value for the healthcare system,” spokeswoman Fiona McMillan told FiercePharma last month. “I know there are concerns about Europe's first gene therapy approval [Glybera] costing around $1 million, but I can say that Strimvelis will be significantly less than that.”


http://www.fiercepharma.com/pharma/glybera-s-a-flop-how-can-other-gene-therapy-developers-avoid-fate